With contributions from leading international academics across the biological sciences, this handbook takes a critical look at the key contemporary issues and debates in the field. The 31 chapters are divided into four parts: Part I Determination of Substance Misuse Part II PK and PD in Relation to Patterns of Use Part III Detection and Treatment of Drug and Alcohol Use Part IV Controversies and New Approaches This Handbook is an excellent reference text for the growing number of academics, students, scientists and practitioners in the drug and alcohol studies community, and will be a vital resource to the allied professions involved in work-place drug testing, clinical toxicology, and forensic science.

Chapter 11: Ketamine: The Pharmacokinetics and Pharmacodynamics in Misusing Populations

Ketamine: The Pharmacokinetics and Pharmacodynamics in Misusing Populations

Ketamine: the pharmacokinetics and pharmacodynamics in medicinal and misusing populations
Kim Wolff


Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone) developed by Parke Davis laboratories in 1962 (Figure 11.1 and 11.2) is a dissociative general anaesthetic derivative of phencyclidine (PCP) available by prescription in the USA since the 1970s for human and veterinary use. Although its use had been thought is limited by emergent psychotomimetic episodes, ketamine is still widely used in acute, neuropathic and palliative care (Niesters et al., 2013; Teasell et al., 2010; Chizh, 2007; Huang et al., 2000; Lloyd-Williams, 2000). There is also growing enthusiasm for the use of ketamine to treat depression and suicidal ideation (Sassano-Higgins et al., 2016). Manufactured as a hydrochloride ketamine has also been utilized in dentistry ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles